ICA Corporate Partners
The generous contributions and support from our corporate partners allow ICA to further its mission to improve the quality of healthcare and lives of people living with IC.
Learn more about how your organization can become an ICA corporate partner.
Aquinox is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Their primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5′-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Their lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and seven clinical trials with AQX-1125, they are now advancing towards pivotal Phase 3 trials with AQX-1125 in their lead indication of bladder pain syndrome/interstitial cystitis (BPS/IC). Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
Desert Harvest’s Super-strength, Freeze-dried Aloe Vera Capsules have been shown in clinical trials to effectively reduce urinary frequency, burning, and pain that are a part of many bladder disorders, but especially interstitial cystitis/painful bladder syndrome (IC/PBS) (sometimes called prostatitis in men and chronic pelvic pain in women).
Prelief® allows so many people to comfortably eat a large array of otherwise provocative foods. Many people are highly sensitive to food acid; for some, various foods can exacerbate urinary problems. Prelief® is a safe, effective over-the-counter product that can allow you to enjoy these foods and stay physically comfortable. Take 2 Prelief® caplets and it will reduce up to 95% of acid in certain beverage/foods by binding to the acid in those foods.
Disclaimer: ICA does not endorse companies, products, or services that may appear on our website.
Revised Monday, March 5th, 2018